Collection of data on the use of a VWF/FVIII concentrate (wilate®) in all clinical applications in von Willebrand disease
Not Applicable
- Conditions
- Von Willebrand disease (VWD)Haematological DisordersVon Willebrand disease
- Registration Number
- ISRCTN11568655
- Lead Sponsor
- Octapharma GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
1. The patient has congenital or acquired Von Willebrand disease (VWD) and requires injections with VWF-containing concentrate (wilate)
2. With a positive bleeding history, other possible causes have been excluded
Exclusion Criteria
1. Patients with known contraindications as specified in the Summary of Product Characteristics (SPC)
2. The patient could actually be treated with DDAVP (Desmopressin Acetate)
3. The patient has a von Willebrand factor activity over 70% and there are no findings manifesting the VWD diagnosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method